Bridgebio Pharma (BBIO) reported $502M in revenue for fiscal 2025, +126.3% year on year. That ranks #2204 by revenue among 2853 SEC filers and #216 in Healthcare. It posted a net loss of −$733M for the same year. Revenue has grown 52.1% a year on average since 2019 ($40.6M then). The fiscal 2025 balance sheet shows $936M in total assets, $570M in cash and $2.0B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $502M | +126.3% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$523M | +$69.6M | FY20252025-12-31 |
| Net incomeProfitLoss | −$733M | −$190M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$446M | +$74.8M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.1M | +17.6% | FY20252025-12-31 |
| Total assetsAssets | $936M | +1.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$2.1B | −$619M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $570M | −16.3% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $2.0B | +359.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $195M | −$167M | Open → |
| Q2 20262026-06-30 | $244M | −$156M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Bridgebio Pharma, Inc.
- Ticker
- BBIO
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001743881
Filings
- 10-QAug 10, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Adma BiologicsADMA | $510M | $147M |
| GlaukosGKOS | $507M | −$188M |
| Starling OncologySTLN | $503M | $60.6M |
| Bridgebio PharmaBBIO | $502M | −$733M |
| Ascend WellnessAAWH | $501M | −$118M |
| Travere TherapeuticsTVTX | $491M | −$25.5M |
| Porch GroupPRCH | $482M | −$3.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bridgebio Pharma — Key figures |url=https://companiesranked.com/en/company/bridgebio-pharma |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bridgebio Pharma — Key figures. CompaniesRanked. https://companiesranked.com/en/company/bridgebio-pharmaBibTeX
@misc{companiesranked-en-company-bridgebio-pharma-2026,
author = {{CompaniesRanked}},
title = {{Bridgebio Pharma — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bridgebio-pharma}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001743881-26-000009 · February 24, 2026
{{cite web |title=Bridgebio Pharma — Key figures — 10-K (0001743881-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.